drugset
drugset / Trial / NCT05686408

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

NCT05686408 ↗

Phase 2 Completed 132 enrolled Tonix Pharmaceuticals, Inc. Rho, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in patients with Major Depressive Disorder (MDD).

Timeline

Start
2023-03-02
Primary completion
2023-09-29
Completion
2023-09-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Tianeptine Small molecule 39.4 mg Oral

Indications

major depressive disorder